Pharmaceutical intermediates
Rucaparib Intermediates
2 pharmaceutical intermediates for Rucaparib. Indication: Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Ovarian cancer.
About Rucaparib
- Originator
- Clovis Oncology Inc
- Indication
- Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Ovarian cancer
- Approved Date
- 12/19/2016
- DS/DP
- 08/12/2027
Available intermediates
2 intermediates currently listed for Rucaparib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Methyl 6-fluoro-1H-indole-4-carboxylate | 1082040-43-4 | / | / |
| 8-Fluoro-1,3,4,5-tetrahydro-6H-pyrrolo[4,3,2-ef][2]benzazepin -6- one | 1408282-26-7 | / | / |
Other programs under R
Building toward Rucaparib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →